DIABESITY DIALOGUES | Patient Perspectives for PCPs: Tackling the Treatment Paradigms of Obesity, T2D, and Other Metabolic Disorders
This activity is supported by an educational grant from Lilly.
Click Here to Manage Email Alerts
CE Activity Release Date: June 09, 2023
CE Activity Expiration Date: June 08, 2024
Time to Complete activity: 60 minutes
ACTIVITY DESCRIPTION
There is an urgent need for effective intervention by healthcare professionals (HCPs) to address the twin epidemics of Type 2 diabetes (T2D) and obesity. Tune into the Diabesity Dialogues vodcast, where renowned physicians, Dr. Robert Kushner, MD, and Dr. Jamy Ard, MD, provide valuable insights on treatment initiation, intensification, and the effective management of diabesity in the presence of other comorbidities. Hear how our esteemed hosts harness the power of social media and discuss the latest information on GLP-1 receptor agonists (RA) and dual GIP/GLP-1 RAs and dispel potential misinformation. In this special feature, tune into patient voices from social media and learn practical tips to enhance patient-centered care and be at the forefront of transformative practices. Don't miss this opportunity to join this cutting-edge conversation.
Ep 1: Benefits Associated with Early Treatment Initiation and Intensification
In this episode, join our esteemed faculty experts as they shed light on the expanding role of primary care physicians in providing comprehensive care to patients with Type 2 diabetes (T2D). Gain valuable insights into best practices for monitoring glucose control and discover how our experts initiate crucial conversations with patients at the time of diagnosis and treatment initiation. Listen to personal stories shared by individuals living with T2D and hear our expert faculty provide practical tips on starting the conversation through actionable advice to optimize patient care.
Ep 2: Twin Epidemics: Prioritization of Obesity as a Treatment Target in T2D
In this episode, join our esteemed faculty experts as they highlight the significance of prioritizing obesity as a treatment target in the management and care of Type 2 diabetes (T2D), delve into the latest clinical evidence surrounding new and emerging pharmacotherapies for weight management, and T2D treatment, and offer practical tips on continuing the conversation by dispelling misconceptions about novel treatments.
Ep 3: It Takes a Village: The Need for Effective Management of T2D and Comorbid Conditions
In this episode, join our esteemed faculty experts as they delve into the realm of effective Type 2 diabetes (T2D) management and comorbidity care and provide strategies to mitigate side effects associated with new and emerging treatments, to ensure optimal patient outcomes. Learn the art of collaborative goal-setting with patients by hearing their personal stories. In addition, faculty experts will provide practical approaches and valuable advice in fostering interprofessional teams to continue the conversation.
Ep 4: Individualizing Care in T2D: Utilizing Patient-reported Outcomes and Shared Decision-Making
In this final episode, join our esteemed faculty experts as they delve into the art of individualizing treatments through shared decision-making. Join us as we explore the importance of considering patient preferences, goals, and values in order to enhance patient satisfaction and adherence to treatment plans. Listen to real-life patient experiences shared through social media and expert faculty provide invaluable advice on evolving the conversation towards a patient-centric approach to T2D and obesity care.
TARGET AUDIENCE
This activity is intended for primary care physicians, NPs, PAs, nurses, and pharmacists who treat individuals with obesity throughout the US.
EDUCATIONAL OBJECTIVES
After completing this CE activity, the participant should be better able to:
- Plan strategies to address unmet needs, including treatment initiation and escalation for patients with T2D and obesity/overweight and other comorbidity risks
- Assess the clinical implications of evidence regarding the incretin effect and the roles of GLP-1 RAs, and dual GLP-1 and GIP in treatment regimens for T2D and obesity
- Relate the pathophysiology of GLP-1 RAs as well as dual GLP-1 and GIP to benefits of agonism of multiple receptors that affect energy homeostasis and the MOA of novel therapies for patients with T2D, obesity and other comorbidity risks
- Implement the use of novel single and dual agonists in treatment regimens for T2D and weight loss
- Interpret the clinical implications of the efficacy and safety data of novel single and dual agonists for T2D
PROGRAM AGENDA
DIABESITY DIALOGUE 1: Benefits Associated with Early Treatment Initiation and Intensification
- The increasing role of primary care physicians in caring for patients with T2D
- Beyond HbA1c: New screening metrics for glucose control in T2D
- The Paradox of T2D Treatment
- Patient Perspective – “What I wish I would have known about my T2D diagnosis” to inspire clinicians to START the conversation with their patients
- PCPs Share Thoughts, Comments, and Best Practices
DIABESITY DIALOGUE 2: Twin Epidemics: Prioritization of Obesity as a treatment target in T2D
- Latest clinical evidence on new and emerging targeted treatments for T2D and obesity
- Selecting the right regimens for patients with T2D
- Patient Perspective – “Dispelling misconceptions in the media” to inspire clinicians to CONTINUE the conversation with their patients
- PCPs Share Thoughts, Comments, and Best Practices
DIABESITY DIALOGUE 3: It Takes a Village: The Need for effective management of T2D and Comorbid conditions
- Disease Management: Mitigating AEs using GLP-1 RA and GIP/GLP-1 RA dual therapy
- Collaborative care: Treatment goal-setting
- T2D Remission: What is it?
- Patient Perspective – “Establishing Patient-centered Care” to inspire clinicians to EVOLVE the conversation with their patients
- PCPs Share Thoughts, Comments, and Best Practices
DIABESITY DIALOGUE 4: Individualizing care in T2D: utilizing patient reported outcomes (PROS) and Shared decision making
- How to talk to patients with T2D about obesity treatment/weight loss
- Talking to patients about the multiple benefits of modest to moderate weight loss
- Patient Perspective – “Patient Advocacy: Addressing Patient Needs” to inspire clinicians to EVOLVE the conversation with their patients
- PCPs Share Thoughts, Comments, and Best Practices
ACCREDITATION, SUPPORT AND CREDIT
In support of improving patient care, Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
Medical Learning Institute, Inc. (MLI) designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Continuing Professional Development
Successful completion of this nursing continuing professional development activity will be awarded 1.0 contact hour and 1.0 contact hour in the area of pharmacology.
Continuing Pharmacy Education
Medical Learning Institute, Inc. designates this continuing education activity for 1.0 contact hour (0.1 CEU) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA0007322-0000-23-046-H01-P
Type of Activity: Knowledge
AAPA Credit Designation Statement
Medical Learning Institute, Inc. has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. Approval is valid until June 8, 2024. PAs should only claim credit commensurate with the extent of their participation.
Certified Diabetes Care and Education Specialists
To satisfy the requirements for renewal of certification for the Certification Board for Diabetes Care and Education (CBDCE), continuing education activities must be diabetes related and approved by a provider on the CBDCE list of Approved Providers (www.cbdce.org). CBDCE does not approve continuing education. ACCME, ANCC and ACPE Accredited Providers are recognized Continuing Education Providers by CBCDE. Medical Learning Institute, Inc. thereby qualifies as a CBDCE Approved Provider.
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.
SUPPORT STATEMENT
This activity is supported by an educational grant from Lilly.
DISCLOSURE & CONFLICT OF INTEREST POLICY
Medical Learning Institute, Inc., is committed to providing high quality continuing education to healthcare professionals, as individuals and teams, with a protected space to learn, teach, and engage in scientific discourse free from influence from ineligible companies that may have an incentive to insert commercial bias into education. To that end, MLI requires faculty, presenters, planners, staff, and other individuals who are in a position to control the content of this CE activity to disclose all financial relationships they have had in the past 24 months with ineligible companies as defined by the ACCME, as related to the content of this CE activity, regardless of the amount or their view of the relevance to the education. All identified COI will be thoroughly vetted and mitigated according to MLI policy. These disclosures will be provided to learners prior to the start of the CE activity.
FACULTY DISCLOSURES
Host Moderator/Planner/PresenterJamy D. Ard, MD
Professor, Department of Epidemiology & Prevention
Wake Forest School of Medicine
Winston-Salem, NC Jamy D. Ard, MD, has a financial interest/relationship or affiliation in the form of:
Advisory Board/Consultant: Boehringer Ingelheim, Intuitive, Lilly, Nestle, Novo Nordisk, UnitedHealth Group, Weight Watchers
Research Grant: Epitomee, KVK Tech, Lilly, Nestle, Weight Watchers
The following relationships have ended within the last 24 months:
Advisory Board/Consultant: Calibrate Host Moderator/Planner/Presenter
Robert F. Kushner, MD
Professor, Departments of Medicine and Medical Education
Northwestern University Feinberg School of Medicine
Chicago, IL
Robert F. Kushner, MD, has a financial interest/relationship or affiliation in the form of:
Advisory Board/Consultant: Altimmune, Boehringer Ingelheim, Lilly, Novo Nordisk, Pfizer, Weight Watchers
Research Grant: Novo Nordisk
Damion Thomas
Damion Thomas has no relevant financial relationships with ineligible companies to disclose for this educational activity. Patient Planner/Presenter
Cecilia Workman
Cecelia Workman has no relevant financial relationships with ineligible companies to disclose for this educational activity. Patient/Planner/Presenter
Jernine Trott
Jernine Trott has no relevant financial relationships with ineligible companies to disclose for this educational activity. Patient Planner/Presenter
Ashton McGrady
Ashton McGrady has no relevant financial relationships with ineligible companies to disclose for this educational activity.
All of the relevant financial relationships of individuals for this activity have been mitigated.
PLANNING COMMITTEE AND CONTENT/PEER REVIEWERS
The planners and content/peer reviewers from Medical Learning Institute, Inc., the accredited provider, do not have any relevant financial relationship(s) to disclose with ineligible companies unless listed below.
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
METHOD OF PARTICIPATION
There are no fees for participating in or receiving credit for this CE activity. In order to receive credit, learners must participate in the entire CE activity, complete the post-test and activity evaluation form and your certificate of credit will be generated. A passing score of 70% or higher is needed to obtain credit. You will receive your certificate from Medical Learning Institute, Inc.
For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.
If you have questions regarding your certificate, please contact MLI at mvu@mlieducation.org.
For Pharmacists, MLI will accept your completed evaluation form for up to 30 days post-activity and will report your participation to the NABP only if you provide your NABP e-Profile number and DOB (MM/DD). Within 6 weeks, you can view your participation record at the NABP website: https://nabp.pharmacy/.
ABOUT THIS ACTIVITY
Medical Learning Institute, Inc. is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this CE activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of this activity is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of Medical Learning Institute, Inc.
The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of Medical Learning Institute, Inc. or any of its partners, providers, and/or supporters.
